Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07201051 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
A Phase 2 study, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 446
- Enrollment target
NCT07201051: Recruiting Phase 2 study, sponsored by GlaxoSmithKline.
NCT07201051 is a Phase 2 study that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 446 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (235% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07201051, a Phase 2 study, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 446 participants
- Enrollment target
Study Summary
This study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease. The study will also test how the body processes the drug and to check for any immune reactions. Participants will be divided into groups randomly to receive either one of two different doses of the study drug or a placebo. The main goal of the study is to see how well the drug works compared to the placebo in helping those with bronchiectasis.
Primary Outcome
Annualized rate of exacerbations for GSK3862995B dose 1 following repeat doses compared with placebo in participants with bronchiectasis will be evaluated.
Interventions
- DRUG Placebo
- DRUG GSK3862995B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 446 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2027-12-10 |
| Phase | Phase 2 |
What NCT07201051 shows while recruiting
NCT07201051 is an interventional study that assigns participants to a tested intervention. The registered 446 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (235% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07201051 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07201051 about?
NCT07201051 is a clinical study titled "A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis". This study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease. The study will also test how the body processes the drug and to check for any immune reactions. Participants will be divided into groups randomly ...
What is the current status of trial NCT07201051?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 446 participants. The study started on 2025-10-30. Estimated completion is 2027-12-10.
What interventions are being tested in trial NCT07201051?
The interventions under investigation include: Placebo (DRUG), GSK3862995B (DRUG).
Who is sponsoring clinical trial NCT07201051?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07201051's enrollment target sits among peer trials
446 89th of 2000 higher than 1,912 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04065399 · 447 participants · Phase 1
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
- NCT03504800 · 445 participants
OCT in Diagnosis of Irregular Corneas
- NCT04751435 · 445 participants · NA
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI